Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

Rhea-AI Summary

Neovasc Inc. (NVCN) announced the results of its Annual General Meeting held on September 3, 2020, in Vancouver. Shareholders re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko, and Fred Colen. The voting results showed a strong majority of votes in favor, with Paul Geyer receiving 92.97% approval. The Company’s share unit plan and previous grants were also approved by 78% and 77.78% of the votes, respectively. Grant Thornton LLP was reappointed as the Company’s auditors. Neovasc develops medical devices for cardiovascular diseases, including the Reducer and Tiara.

Positive

• Strong shareholder support with over 80% votes in favor for board members.
• Approval of share unit plan with 78% support.
• Reappointment of Grant Thornton LLP as auditors indicates confidence.

Negative

• None.

Vancouver, BC, Canada, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the “Meeting”).

At the Meeting, the shareholders of the Company (the “Shareholders”) re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Steven Rubin	5,744,656	80.53	1,388,972	19.47
Paul Geyer	6,632,055	92.97	501,573	7.03
Doug Janzen	6,702,438	93.96	431,190	6.04
Norman Radow	6,693,984	93.84	439,644	6.16
Alexei Marko	6,497,336	91.08	636,292	8.92
Fred Colen	6,613,038	92.70	520,590	7.30

At the Meeting, the Shareholders also approved the Company’s share unit plan (78.00% of votes cast in favour), the Company’s previous grants of share units (77.78% of votes cast in favour) and re-appointed Grant Thornton LLP, Chartered Accountants as auditors of the Company.

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.

Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com

Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, expectations as to the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three months ended June 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

What were the results of Neovasc's Annual General Meeting on September 3, 2020?

Neovasc shareholders re-elected board members and approved the share unit plan, with strong majority votes.

How did the shareholders vote for board members at Neovasc's AGM?

Votes ranged from 80.53% to 92.97% in favor of re-elected board members.

Who were re-elected to the board of Neovasc during the AGM?

Board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko, and Fred Colen were re-elected.

What percentage of votes approved Neovasc's share unit plan?

The share unit plan was approved by 78% of the votes cast.

What does Neovasc focus on in its business?

Neovasc develops medical devices for cardiovascular conditions, including the Reducer and Tiara.